PRGO
Perrigo Company plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IE
$14.92
+4.56%Aug 5, 2026, 10:30 UTC
Perrigo Company plc reported financial results from continuing operations for the second quarter ended June 27, 2026, highlighting market share growth in U.S. store-brand OTC and key European brands, completion of the Dermacosmetics divestiture, and reaffirmed full-year 2026 outlook.
Jul 30, 2026, 12:30 UTC
Perrigo Company plc announced a quarterly dividend of $0.29 per share, payable on September 15, 2026, to shareholders of record on August 28, 2026.
Source:Jun 30, 2026, 20:25 UTC
Perrigo Company plc appointed Salman Amin and Omer Gajial as independent directors to its Board, effective June 30, 2026.
Source:Jun 8, 2026, 20:18 UTC
Perrigo Company plc appointed Albert A. Manzone as Interim President and CEO, effective immediately, following the resignation of Patrick Lockwood-Taylor as President and CEO and as a board member.